🇺🇸

US SEC Filing Intelligence

· daily

US Executive Compensation Proxy SEC Filings — September 09, 2026

This digest covers seven DEF 14A filings, primarily focused on routine director elections and auditor ratifications, with two exceptions that present material, actionable events: the pending $3.4 billion acquisition of Atkore (ATKR) by Prysmian and a critical reverse stock split proposal at micro-cap Dror Ortho-Design (DROR). The majority of filings (CNL, T. Rowe Price OHA, Federated Hermes, Kearny Financial, and Aehr Test Systems) contain no financial results, insider trading activity, forward-looking statements, or novel period-over-period comparisons in their proxy statements, rendering them low-materiality for investment purposes. Conversely, Atkore’s filing carries exceptionally high materiality (9/10) due to a binding shareholder vote on a company sale, while Dror’s filing is moderately material (6/10) due to a deep dilution and a necessity-level reverse split vote. The overarching theme is a split between passive governance events and two high-stakes corporate actions that require active investor response.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 09, 2026

The IPO pipeline on September 9, 2026, is characterized by a high degree of heterogeneity, spanning clinical-stage biotech, a micro-cap tech turnaround, and two blank-check SPACs. The most material development is MapLight Therapeutics' S-1, which follows positive Phase 2 data for its CNS candidate, though its lack of revenue and history of losses create a high-risk/high-reward profile. A notable negative signal is SOBR Safe's S-1, filed amid a going-concern warning, discontinued operations, and a pivot to a merger, indicating severe financial distress. The two SPAC filings (Harbour Island and Football Manager) highlight continued, albeit cautious, appetite for blank-check vehicles, with Football Manager targeting a substantial $100M raise. No period-over-period financial trends are available as all filers are pre-revenue or have no disclosed historical financials in these registration statements. The overarching theme is a bifurcated pipeline: one high-quality, data-driven biotech IPO versus several speculative or distressed offerings, demanding rigorous due diligence.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — September 09, 2026

The sole filing for this session, Iveda Solutions' 8-K regarding a second 180-day grace period from Nasdaq, represents a procedural lifeline rather than a definitive event. While not a trading suspension or delisting itself, it is a critical pre-delisting development with a materiality score of 9/10. The extended deadline to March 1, 2027, provides a temporary reprieve but underscores the company's persistent failure to meet the minimum $1.00 bid price rule. The negative sentiment and lack of guaranteed compliance highlight a high-risk situation. No period-over-period trends, insider activity, or capital allocation data were available in the enriched filing to provide broader portfolio-level insights, making this a singular, company-specific watch item.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — September 09, 2026

The September 9, 2026 batch of 26 filings reveals a pronounced wave of board refreshment and C-suite succession across US-listed companies, with 18 new filings and 8 context items. Key themes include strategic board appointments (Amazon, Teleflex, AT&T, Ball, BJ's), CFO transitions (Lyft, Fortune Brands, Cornerstone, CME), and leadership restructuring (Coronado, Essential Properties, electroCore). Notable forward-looking catalysts include Genuine Parts' planned separation (Q1 2027), Rallybio's merger with Avenzo, and Century Therapeutics' IND submission for CNTY-813 (Q4 2026). While most changes are neutral-to-positive, several carry transition risk, particularly the departure of Essential Properties' CIO and the part-time CFO transition at Rallybio. Insider activity is limited, but the RSU grant to AEye's CFO and the performance-based awards to Fortune Brands' new CFO signal retention incentives. Overall, the digest points to a market favoring companies with strong governance refreshment and clear strategic direction, while flagging execution risks in transitional periods.

26 high priority 26 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 09, 2026

This digest covers 26 SEC filings focused on board room changes, with 18 new filings and 8 for context. The dominant theme is board refreshment and executive succession planning, with several high-profile appointments including Meg Whitman at Albertsons, Kevin Mandia at Amazon, and a new CEO at Weight Watchers. A significant corporate action is Genuine Parts Company's planned separation into two independent public companies, with leadership teams announced and investor days scheduled. The filings reveal a trend of companies bringing in specialized expertise (cybersecurity, medical technology, brand marketing) and promoting from within for key financial roles. Notable insider activity includes a one-time RSU grant to AEye's CFO tied to commercial progress, and a CFO transition to part-time at Rallybio ahead of a merger. No period-over-period financial comparisons were available in these governance-focused filings, limiting quantitative trend analysis. The overall sentiment is cautiously positive, with most changes aimed at strengthening leadership and strategic direction.

26 high priority 26 total filings
· daily

USA Insider Trading Pulse — September 09, 2026

Today's 'USA Insider Trading Pulse' is dominated by a massive, coordinated wave of open-market purchases by 27 officers of Taiwan Semiconductor Manufacturing Co. (TSMC) at a uniform $76.20 price point, sending an overwhelmingly bullish signal from the semiconductor powerhouse's executive ranks. This cluster of insider buying, totaling ~$107K across 27 transactions, is the most significant signal across the 50 filings and strongly suggests management conviction in the company's near-term prospects. In stark contrast, significant bearish signals emerge from high-level executives at Sea Ltd (COO sold $1.38M) and Keysight Technologies (SVP sold $652K), both executed via 10b5-1 plans, indicating pre-planned but notable portfolio diversification. The filing set also reveals major equity awards at ASE Technology Holding Co. (1.875M shares granted to 8 executives), a tax withholding sale at Innovex International ($152K), and a planned sale by a LA-Z-BOY director ($116K). While numerous filings are of low individual materiality, the aggregate pattern across TSMC is a standout positive cluster, while sales at Sea Ltd and Keysight warrant closer monitoring.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 09, 2026

The September 9, 2026 filing set reveals a pronounced acceleration in SPAC activity, with three distinct transactions—two new business combination announcements (Daedalus/HubX, Unite/Blue Laser Fusion) and one extension vote (Alchemy)—highlighting a market still actively seeking and completing de-SPAC deals. The successful tender offer and short-form merger of Selectis Health by Black Pearl Equities at $5.75/share (90.93% tendered) demonstrates a clean, fully-cashed-out acquisition, while Barinthus Biotherapeutics' scheme of arrangement marks a completed cross-border take-private with a stock-for-stock exchange. Notably, no filing disclosed specific financial metrics (revenue, margins, or period-over-period comparisons), indicating a data-scarce environment where qualitative signals—such as Point72's $75M investment commitment in HubX and the unqualified audit opinion for Blue Laser Fusion—carry outsized weight. The extension votes (Alchemy to Sept 2027, Andretti to 36 months from IPO) reflect a broader trend of SPACs buying time to secure quality targets, reducing liquidation risk but extending capital lock-up periods. Overall, the digest points to a bifurcated market: high-quality targets attracting institutional backing (HubX, Blue Laser Fusion) versus cash-strapped SPACs (Alchemy, Andretti) relying on extensions to avoid returning capital. Investors should focus on the execution risk of pending deals and the strategic rationale behind take-privates, as financial disclosures remain limited.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 09, 2026

The overnight filing cycle from September 8-9, 2026, reveals a market dominated by significant insider selling, particularly concentrated in the technology sector, where Silver Lake entities executed a coordinated, multi-faceted sell-down of Dell Technologies Inc. shares totaling over $36 million across multiple filings. This aggressive disposition by a major director, combined with substantial sales at Cloudflare and Sandisk, signals potential sector rotation or profit-taking by sophisticated investors. Conversely, a notable insider buy at Enovis Corp and a director purchase at ASTROTECH Corp provide isolated bullish signals. The period also features transformative corporate actions, including the full acquisition of Selectis Health at a 90.93% tender success rate and the proposed de-SPAC merger of General Fusion with Spring Valley Acquisition Corp. III, alongside a high-risk delisting notice for Premium Catering. Financially, ASE Technology Holding Co., Ltd. reported exceptional growth with revenues surging 45.7% YoY, while VolitionRx faces severe dilution risks from covenant breaches and down-round adjustments. The overall sentiment is cautious, with a clear theme of cash extraction by insiders and a focus on capital returns through buybacks at Novo Nordisk and KT Corp.

35 high priority 15 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 08, 2026

During the week of September 8, 2026, the FDA approved five products, with a mix heavily skewed toward biosimilar entries (4 approvals) and one high-conviction NME. The dominant therapeutic theme is absent as approvals span diverse mechanisms (neurology, bone health, psychiatry, cardiovascular). The highest-conviction signal is the NME approval of ZILGANERSEN (IONIS PHARMS INC) for an undisclosed indication, granted Priority Review, representing a significant commercial catalyst for Ionis and validating its antisense platform. Key risks include the competitive pressure from four biosimilar approvals—RELUGOLIX (SANDOZ INC), ALENDRONATE SODIUM (PRECISION DOSE INC), PIMAVANSERIN (TEVA PHARMS USA), and SACUBITRIL (AUROBINDO PHARMA LTD)—which will erode originator revenues in their respective markets. Investors should watch for launch dynamics and payer coverage decisions for ZILGANERSEN, as well as the pace of biosimilar uptake for the other four agents.

5 total filings
· daily

NME Blockbuster Approvals — September 08, 2026

During the period of September 08, 2026, the FDA approved one NME, ZILGANERSEN (ZANVASTRO) from IONIS PHARMS INC, which received Priority Review, signaling a strong unmet need and a bullish investment signal. The approval mix was 0 NMEs, 0 biosimilars, and 0 label expansions, with 1 'Other' approval type (likely a fallback classification). The dominant therapeutic area theme is not clearly defined due to the single approval, but the Priority Review designation underscores the potential commercial significance. The highest-conviction signal is the approval of ZILGANERSEN, which could represent a new revenue stream for Ionis, though commercial details remain undisclosed. Key watch items include the lack of disclosed peak sales, exclusivity, and pricing data, which are critical for assessing market potential.

1 total filings
· daily

New Drug Approvals (Original) — September 08, 2026

During the period of September 08, 2026, the FDA issued five original approvals, all classified as 'Other' with no NMEs, biosimilars, or label expansions formally identified. The highest-conviction signal is the bullish NME approval of ZILGANERSEN (ZANVASTRO) by Ionis Pharmaceuticals, which received Priority Review and represents a significant commercial opportunity for the sponsor. The remaining four approvals—RELUGOLIX (Sandoz), ALENDRONATE SODIUM (Precision Dose), PIMAVANSERIN (Teva), and SACUBITRIL (Aurobindo)—are neutral signals, likely representing generic or biosimilar entries that could introduce competitive pressures in their respective markets. Key watch items include the commercial execution of ZILGANERSEN and the potential market impact of the multiple 'Other' approvals. No dominant therapeutic area theme emerges, though the mix of approvals suggests a steady regulatory cadence across diverse drug classes.

5 total filings
· daily

New Federal Contractors — September 08, 2026

This digest covers a single $210.2 million civilian sector contract awarded to North Wind Portage, Inc. by the Department of Energy (DOE) for environmental remediation at the Moab and Crescent Junction sites. The contract is not defense-related, marking a pure civilian signal with a neutral sentiment (strength 5/10). As a firm-fixed-price delivery order under a small business set-aside, execution risk is elevated despite DOE’s robust long-term cleanup mandate. The highest-conviction signal is the partial outlay of $66.5 million (32% completion), suggesting either slower-than-expected progress or efficient cost management, but no bullish or bearish extremes are present. Key risk is the fixed-price structure for high-cost radioactive material handling; watch for option exercises beyond the original 2022 performance end date.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 08, 2026

The sole contract in this digest is a $210.2 million firm-fixed-price delivery order awarded to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, by the Department of Energy for environmental remediation at the Moab and Crescent Junction sites in Utah. This is a civilian agency award (0/1 defense-related), reflecting continued DOE investment in legacy site cleanup. The contract, awarded in 2016 with performance through March 2022, shows only $66.5 million outlayed (about 32% completion), indicating potential execution delays or slow spend. The highest-conviction signal is the neutral outlook for North Wind Portage given the fixed-price structure and small business designation, which introduces execution risk but also potential efficiency upside. Key watch items include contract extension or option exercise beyond March 2022 and DOE budget allocations for environmental management, which will determine follow-on opportunities.

1 total filings
· daily

Contract Deobligations Alert — September 08, 2026

The sole contract in this period is a $210.2 million firm-fixed-price delivery order from the Department of Energy (DOE) to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, for environmental remediation at the Moab and Crescent Junction sites in Utah. This is a civilian contract (0/1 defense-related), reflecting ongoing DOE environmental management spending on legacy site cleanup. The contract, awarded in 2016 with performance through March 2022, shows $66.5 million outlayed (~32% completion), indicating partial execution and potential for follow-on work. The highest-conviction signal is the stable, long-term nature of DOE environmental remediation, though the fixed-price structure and small business designation introduce execution risk and limited scalability. Key watch items include potential contract extensions beyond March 2022 and DOE budget allocations for environmental management.

1 total filings
· daily

Contract Option Exercises — September 08, 2026

This digest covers a single $210.2 million contract option exercise from the Department of Energy (DOE) to North Wind Portage, Inc., a small business joint venture with Leidos. The contract is entirely civilian, with zero defense-related awards, reinforcing a stable but low-growth theme in DOE environmental remediation. The highest-conviction signal is neutral: the firm-fixed-price structure and 32% completion rate suggest manageable execution risk but limited upside for investors. A key risk is the contract's original performance period ending in March 2022, implying potential delays or extensions that could signal cost overruns or budget reallocations.

1 total filings
· daily

All DOE Contracts — September 08, 2026

The single Department of Energy (DOE) contract analyzed for September 8, 2026, totaling $210.2 million, underscores a civilian-sector environmental remediation theme with zero defense exposure. The award to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, is a firm-fixed-price delivery order for Moab and Crescent Junction site cleanup, with only $66.5 million outlayed (32% completion) as of the data snapshot. The highest-conviction signal is neutral, reflecting stable DOE environmental management spending but tempered by execution risk from the fixed-price structure and limited scalability due to the small business designation. A key risk is the contract's 2022 performance end date, leaving investors to monitor whether options were exercised or follow-on awards materialized.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 08, 2026

The sole contract in this digest is a $210.2 million firm-fixed-price delivery order awarded to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, by the Department of Energy for environmental remediation at the Moab and Crescent Junction sites in Utah. This is a civilian award (0/1 defense-related), reflecting ongoing DOE environmental management spending on legacy site cleanup. The contract, awarded in 2016 with a performance period through March 2022, has $66.5 million outlayed, indicating about 32% completion. The highest-conviction signal is the stable, long-term nature of DOE environmental management, but the firm-fixed-price structure and small business designation introduce execution risk and limited scalability. Key watch items include potential contract extensions or option exercises and DOE budget allocations for environmental management.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 08, 2026

The sole contract in this period is a $210.2 million firm-fixed-price delivery order from the Department of Energy to North Wind Portage, Inc., a small business joint venture under North Wind-Leidos JV LLC, for environmental remediation at the Moab and Crescent Junction sites. With zero defense-related awards, the digest is entirely civilian, reflecting ongoing DOE environmental management spending. The highest-conviction signal is neutral: the award signals stable but low-tech remediation demand, but the fixed-price structure and partial completion (32%) introduce execution risk for a small business. Key watch items include whether options were exercised beyond the March 2022 performance end and DOE budget trends for legacy site cleanup.

1 total filings
· daily

DOE Energy Grants — September 08, 2026

The digest covers a single $210.2 million civilian contract from the Department of Energy to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, for environmental remediation at the Moab and Crescent Junction sites. This award is entirely civilian (0/1 defense-related) and reflects ongoing DOE environmental management spending, a stable but low-growth sector. The highest-conviction signal is neutral, given the firm-fixed-price structure that introduces execution risk and the partial completion status (32% outlayed). A key risk is the contract's 2022 expiration, with no clear indication of follow-on awards, which could signal a gap in revenue for the contractor.

1 total filings
· daily

General Federal Contracts — September 08, 2026

This digest covers a single $210.2 million civilian contract awarded to North Wind Portage, Inc. by the Department of Energy for environmental remediation at the Moab and Crescent Junction sites. The contract is fully civilian, with no defense-related awards, and the aggregate signal strength is neutral at 5.0/10. The highest-conviction signal is the fixed-price structure, which introduces execution risk for the small business contractor, while the partial outlay of $66.5 million suggests about 32% completion. Key risks include potential cost overruns under the firm-fixed-price terms and the uncertainty of follow-on contracts beyond the original March 2022 performance period.

1 total filings